Samsara Reports 3.1% Stake in Palvella (PVLA) — 339,743 Shares

Rhea-AI Filing Summary

Palvella Therapeutics, Inc. (PVLA) disclosed a Schedule 13G/A reporting that Samsara BioCapital, L.P., Samsara BioCapital GP, LLC and Srinivas Akkaraju together beneficially own 339,743 shares of common stock, representing 3.1% of the class based on 11,055,665 shares outstanding as of May 9, 2025. The filing states Samsara LP directly holds the shares, Samsara GP is the general partner and Dr. Akkaraju is a managing member, and that the holdings were not acquired to change or influence control of the issuer.

The filing is dated for the reporting event as of June 30, 2025 and signatures show execution on August 14, 2025. The reporting address is c/o Samsara BioCapital, LLC, Palo Alto, CA.

Insights

Financial Analyst

TL;DR: A passive investor group reports a small, non-control stake of 3.1% in PVLA.

The Schedule 13G/A indicates a collective holding of 339,743 shares, or 3.1% of Palvella's outstanding common stock, which is below the 5% threshold commonly treated as more material for activist or control considerations. The filing expressly disclaims acquisition for control and follows passive-investor reporting practice. For market impact, this holding size is unlikely to materially affect capitalization or voting outcomes absent further purchases or changes in intent.

Corporate Governance Expert

TL;DR: Reporting persons have shared voting/dispositive power but claim no intent to influence control.

The filing clarifies the governance relationships: Samsara GP is general partner of Samsara LP and Dr. Srinivas Akkaraju is a managing member, giving shared voting and dispositive power over the reported shares. The certification states the shares were not acquired to change control, and the joint filing agreement is referenced. Governance implications are limited given the 3.1% position and the passive filing status.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PVLA shares do Samsara BioCapital and related parties report owning?

The reporting persons state beneficial ownership of 339,743 shares, equal to 3.1% of Palvella's common stock based on 11,055,665 shares outstanding.

Does the Schedule 13G/A indicate an intent to influence control of Palvella (PVLA)?

No. The filing includes a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Who are the reporting persons on the PVLA Schedule 13G/A?

The reporting persons are Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, and Srinivas Akkaraju.

What date is used for the ownership reported in the PVLA filing?

The aggregate ownership is reported as of June 30, 2025, with signatures dated August 14, 2025.

Where is the reporting person's principal business address listed?

The address provided is c/o Samsara BioCapital, LLC, 628 Middlefield Road, Palo Alto, CA 94301.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 05:26 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Palvella Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

697947109

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 697947109

1

Names of Reporting Persons

Samsara BioCapital, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 339,743.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 339,743.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

339,743.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.1 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 697947109

1

Names of Reporting Persons

Samsara BioCapital GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 339,743.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 339,743.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

339,743.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 697947109

1

Names of Reporting Persons

Srinivas Akkaraju

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 339,743.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 339,743.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

339,743.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Palvella Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 125 Strafford Ave, Suite 360, Wayne, PA, 19087.
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the "Reporting Persons") are: Samsara BioCapital, L.P. ("Samsara LP") Samsara BioCapital GP, LLC ("Samsara GP") Srinivas Akkaraju ("Dr. Akkaraju") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
(b)	Address or principal business office or, if none, residence: c/o Samsara BioCapital, LLC 628 Middlefield Road Palo Alto, CA 94301
(c)	Citizenship: Samsara LP Delaware Samsara GP Delaware Dr. Akkaraju United States
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 697947109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. Samsara LP directly holds 339,743 shares of common stock. Samsara GP is the sole general partner of Samsara LP and Dr. Akkaraju is a managing member of Samsara GP. Each of Samsara GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara LP.
(b)	Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025, and is incorporated by reference. The percentage set forth in each row 11 is based upon 11,055,665 shares of common stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 15, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025, and is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025, and is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025, and is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025, and is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Samsara BioCapital, L.P.

Signature:	/s/ Srinivas Akkaraju
Name/Title:	By Samsara BioCapital GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member
Date:	08/14/2025

Samsara BioCapital GP, LLC

Signature:	/s/ Srinivas Akkaraju
Name/Title:	By Srinivas Akkaraju, Managing Member
Date:	08/14/2025

Srinivas Akkaraju

Signature:	/s/ Srinivas Akkaraju
Name/Title:	Srinivas Akkaraju
Date:	08/14/2025

Exhibit Information

Exhibit 99.1 Joint Filing Agreement, dated as of December 20, 2024 (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on December 20, 2024).